Cardiovascular Diseases Industry in India Share, Trends & Forecast to 2026


Posted November 7, 2020 by rishabh3210

Cardiovascular Diseases Industry in India Share, Trends & Forecast to 2026Cardiovascular Diseases Industry in India Share, Trends & Forecast to 2026

 
Cardiovascular diseases (CVDs) are amongst the fatal diseases across the globe, accounting for over 25% of the total mortalities in India every year. The Harvard School of Public Health (HSPH) and the World Economic Forum (WEF) revealed that between 2012 and 2030, the total economic burden of non-communicable diseases in India is estimated to reach $1.7 trillion (INR 126 lakh crore). CVD includes high blood pressure, coronary artery disease, cardiac arrest, stroke, arrhythmia, congestive heart failure, peripheral artery disease, and congenital heart disease. The high blood pressure is the most prevalent in India. Therefore, there is a significant demand for anti-hypertensive drugs in the Indian CVD market. In conjunction with the management of high blood pressure, the chances reduces for the occurrence of other chronic health conditions, such as stroke, heart attack, or other complications.

Get Free Sample Copy @ https://marketinsight.in/request-sample/indian-cardiovascular-diseases-industry-outlook

As per the Institute for Health Metrics and Evaluation (IHME), CVD's risk factors have increased across all states in India between 1990 and 2017. In less developed Indian states, such as Bihar, Rajasthan, Meghalaya, Jharkhand, Uttar Pradesh, Assam, Madhya Pradesh, Chhattisgarh, and Odisha, the prevalence of the CVD is comparatively less, with the prevalence of the disease varied between 3,000 and 4,000 per one million population in 2017.

A Full Report of Indian Cardiovascular Diseases Industry is Available at: https://marketinsight.in/industry-reports/indian-cardiovascular-diseases-industry-outlook

MAJOR CATEGORIES IN THE CVD THERAPY

i) Lipid Medications (Statins)

ii) Angiotensin Receptor Blockers (Sartans)

iii) Beta-Blockers

iv) Anticoagulants

Whereas beta-blockers are used to treat various conditions such as hypertension, arrhythmia, chest pain, and migraine, among others. This CVD drug therapy accounts for nearly 20% of the Indian CVD drug market, as per OMR analysis. The major key players active in the Indian CVD drug market include Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals, Ltd., Lupin, Ltd., USV Pvt., Ltd., and Glenmark Pharmaceuticals, Ltd. Company-wise, Sun Pharmaceutical Industries Ltd. is the largest player in CVD drugs with around 15% market share in the Indian CVD drug market in 2020.

For More Customized Data, Request for Report Customization @ https://marketinsight.in/report-customization/indian-cardiovascular-diseases-industry-outlook

About Market Insight

Marketinsight.in, a sub-division of Orion Market Research (OMR), is a determined market research firm that simply aims at providing services such as consulting, customize research, field research and a growth strategy plan to the Indian enterprises. It provides a complete suite of customized services focused on to bringing process efficiency and market effectiveness in its services.

Media Contact:
Company Name: Market Insight
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Rishabh
Phone +91 780-304-0404
Country India
Categories Business
Tags cardiovascular diseases industry in india share , trends forecast to 2026
Last Updated November 7, 2020